Solving COVID: April 21, 2021
Booster shots, over-the-counter rapid tests, and more
- 1. Where things stand
- 2. Pfizer CEO says COVID-19 vaccine booster dose 'likely' necessary within 12 months
- 3. Over-the-counter rapid COVID tests arrive at Walgreens, Walmart, and CVS
- 4. J&J to resume Europe vaccine rollout
- 5. A new Oxford study will deliberately reinfect recovered COVID-19 patients
1. Where things stand
On Monday, every adult over the age of 16 in the United States became eligible for the COVID-19 vaccine, marking a milestone in America's aggressive vaccination program. The nation has so far administered at least one dose to nearly 50 percent of the eligible population, according to The Washington Post. Daily cases remain steady at about 60,000, but daily deaths have fallen to about 700, down from a peak of more than 3,000 in January, CNBC reports. Unfortunately, the global outlook is worrisome: Last week was the worst yet for global infections, led by out-of-control surges in India and Brazil. With 5.2 million new weekly cases, "the data from Johns Hopkins University showing a 12 percent increase in infections from a week earlier casts doubt on the hope that the end of the pandemic is in sight," writes Jinshan Hong at Bloomberg.
2. Pfizer CEO says COVID-19 vaccine booster dose 'likely' necessary within 12 months
Pfizer CEO Albert Bourla says people will "likely" need to get a COVID-19 vaccine booster dose within 12 months after they've been fully vaccinated, CNBC reported on Thursday. "It is extremely important to suppress the pool of people that can be susceptible to the virus," he said. Bourla also reportedly said it's possible that getting vaccinated against COVID-19 annually will be necessary. Previously, Pfizer said that an analysis of a phase 3 study found that its COVID-19 vaccine remained highly effective at least six months after the second dose. Dr. Anthony Fauci has explained it's "highly likely that it will be effective for a considerably longer period of time," but "we very well may need to get booster shots to keep up the level of protection."
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
3. Over-the-counter rapid COVID tests arrive at Walgreens, Walmart, and CVS
Prescription-free rapid COVID-19 tests that can be taken at home will be on sale at some Walgreens, Walmart, and CVS stores starting this week. One test kit, produced by Abbott Laboratories, will be sold at all three retailers, as well as online, while CVS stores in Rhode Island and Massachusetts will sell another test made by the Australia-based company Ellume. The latter will be available online and in other states by the end of May, USA Today notes. The benefits of the tests are clear — people don't need to visit a doctor or testing center, and both deliver results in about 15 minutes. There are concerns, though. For starters, antigen tests are less reliable than PCR tests, and while that issue could be countered by taking multiple at-home tests, both kits are fairly expensive. Abbott's costs $23.99 and Ellume's has a price tag of $38.99.
4. J&J to resume Europe vaccine rollout
Johnson & Johnson said Tuesday that it planned to resume distribution of its coronavirus vaccine in Europe. Regulators there found a link to rare blood clots, but said the vaccine's benefits outweighed the risks of side effects. Johnson & Johnson paused the shot's rollout in the European Union after U.S. agencies recommended a delay of the vaccine's use pending review of the blood clot concerns. The European Medicines Agency's latest recommendation is not binding, but it cleared the way for the block's 27 member states to decide whether to use the vaccine, according to their case load and access to other vaccines. Johnson & Johnson's single-shot vaccine already has been administered to nearly eight million Americans. The pause with Johnson & Johnson's product hampered an already troubled EU vaccination effort, following the suspension of AstraZeneca's vaccine over similar clotting concerns.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
5. A new Oxford study will deliberately reinfect recovered COVID-19 patients
Researchers at the University of Oxford are looking for 64 healthy people between the ages of 18 and 30 who have recovered from COVID-19. In a new, first-of-its kind study, the volunteers will be reinfected with the original strain of the coronavirus first identified in Wuhan, China, under controlled, quarantined conditions for 17 days, the university said Monday. The main goal of the challenge trial is to discover what levels and types of immunity are needed to prevent reinfection, which could aid vaccine developers going forward. So far, natural infections and vaccines appear to provide strong protection against reinfection in most cases, but it's unclear how long that will last. The study may also reveal how much virus it takes to reinfect a recovered patient. While Oxford is excited about the study's potential, challenge trials have their critics, who argue that deliberately infecting someone is unethical, regardless of the circumstances.
Create an account with the same email registered to your subscription to unlock access.
-
'Voters know Biden and Trump all too well'
Instant Opinion Opinion, comment and editorials of the day
By Harold Maass, The Week US Published
-
Is the Gaza war tearing US university campuses apart?
Today's Big Question Protests at Columbia University, other institutions, pit free speech against student safety
By Joel Mathis, The Week US Published
-
DOJ settles with Nassar victims for $138M
Speed Read The settlement includes 139 sexual abuse victims of the former USA Gymnastics doctor
By Justin Klawans, The Week US Published
-
Nigeria's worsening rate of maternal mortality
Under the radar Economic crisis is making hospitals unaffordable, with women increasingly not receiving the care they need
By Harriet Marsden, The Week UK Published
-
Dengue hits the Americas hard and early
Speed Read Puerto Rico has declared an epidemic as dengue cases surge
By Peter Weber, The Week US Published
-
How happy is Finland really?
Today's Big Question Nordic nation tops global happiness survey for seventh year in a row with 'focus on contentment over joy'
By Harriet Marsden, The Week UK Published
-
How Tehran became the world's nose job capital
Under the radar Iranian doctors raise alarm over low costs, weak regulation and online influence of 'Western beauty standards'
By Harriet Marsden, The Week UK Published
-
Africa's renewed battle against female genital mutilation
Under the radar Campaigners call for ban in Sierra Leone after deaths of three girls as coast-to-coast convoy prepares to depart
By Harriet Marsden, The Week UK Published
-
Argentina: the therapy capital of the world
Under the radar Buenos Aires natives go hungry to pay for psychoanalysis, amid growing instability, anxiety – and societal acceptance
By Harriet Marsden, The Week UK Published
-
Does declining birth rate spell doom for Britain?
Today's Big Question Ageing population puts pressure on welfare state, economy and fabric of society, while fertility is rising on populist agendas
By Harriet Marsden, The Week UK Published
-
How a new blood test could revolutionise sepsis diagnosis
The Explainer Early results from ongoing trial suggest faster identification of deadly condition is possible
By The Week Staff Published